Targets of therapy in progressive MS
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Highly effective anti-inflammatory therapies have so far been developed for patients with relapsing/remitting multiple sclerosis, which also show some benefits in the early progressive stage of the disease. However, treatment options for patients, who have entered the progressive phase, are still limited. Disease starts as an inflammatory process, which induces focal demyelinating lesions in the gray and white matter. This stage of the disease dominates in the relapsing phase, extends into the early stages of progressive disease, and can be targeted by current anti-inflammatory treatments. In parallel, inflammation accumulates behind a closed or repaired blood brain barrier, and this process peaks in the late relapsing and early progressive stage and then declines. Some data suggest that this process may be targeted by immune ablation and hematopoietic stem cell transplantation. In the late stage, inflammation may decline to levels seen in age-matched controls, but age and disease burden–related neurodegeneration ensues. Such neurodegeneration affects the damaged brain and spinal cord, in which functional reserve capacity is exhausted, giving rise to further disability progression. Anti-inflammatory treatments are unlikely to be beneficial in this stage of the disease, but neuroprotective and repair-inducing strategies may still be effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationThe relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Self-citationSerafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Inflammatory cortical demyelination in early multiple sclerosis.
Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100648 · Cited by 1,103
Self-citationTissue-Resident Memory T Cells
Schenkel, J. M., & Masopust, D. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.007 · Cited by 1,059
Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.393 · Cited by 951
Self-citationMeningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., Aloisi, F., & Reynolds, R. (2010) · Annals of Neurology · doi:10.1002/ana.22230 · Cited by 747
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Self-citation
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Böttcher, C., van der Poel, M., Fernández-Zapata, C., Schlickeiser, S., Leman, J. K. H., Hsiao, C.-C., Mizee, M. R., Adelia, Vincenten, M. C. J., Kunkel, D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01010-8 · Cited by 58
Wu, X., Chen, Z., Liao, Y., Yang, Z., Liang, X., Guan, N., & Gan, Z. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1063479 · Cited by 23
“Supposing BD was an inflammatory disease as someone claimed (22), the serum levels of inflammatory markers would first increase with the worsening of symptoms and then decrease because of exhaustion with the evolvement of illness like other inflammatory diseases (23).”
BackgroundAmmitzbøll, C., Dyrby, T. B., Börnsen, L., Schreiber, K., Ratzer, R., Romme Christensen, J., Iversen, P., Magyari, M., Lundell, H., Jensen, P. E. H., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104854 · Cited by 20
Metadata
- Authors
- Lassmann, H.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2017-10
- Volume
- 23
- Issue
- 12
- Pages
- 1593-1599
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2767151013
- Cited by
- 82
- References
- 24
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targets of therapy in progressive MS. https://app.cochat.ai/papers/10.1177/1352458517729455
- The paper
- Lassmann, H. (2017). Targets of therapy in progressive MS. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458517729455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.